摘要
目的探讨托伐普坦联合沙库巴曲缬沙坦钠在慢性心力衰竭(chronic heart failure,CHF)患者中的应用价值。方法本研究选取2020年9月—2023年9月在巨野县人民医院接受基础治疗+沙库巴曲缬沙坦钠+托伐普坦用药方案治疗的61例CHF患者作为联合用药组,同期选取接受基础治疗+沙库巴曲缬沙坦钠用药方案治疗的37例CHF患者作为单一用药组;比较两组临床疗效、心功能及不良反应发生率情况,比较两组治疗前后24 h尿量及血钠水平。结果治疗后,联合用药组治疗总有效率91.80%(56/61)高于单一用药组的75.68%(28/37),差异有统计学意义(P<0.05);联合用药组美国纽约心脏病学会分级(New York Heart Association,NYHA)Ⅰ~Ⅱ为91.80%(56/61)高于单一用药组的67.57%(25/37),差异有统计学意义(P<0.05)。治疗前,两组24 h尿量、血钠水平比较,差异无统计学意义(P>0.05);治疗后,联合用药组24 h尿量、血钠水平高于单一用药组,差异有统计学意义(P<0.05)。两组患者治疗期间均未发生严重不良反应。结论与单一用药相比,将托伐普坦、沙库巴曲缬沙坦钠联合用药方案用于CHF患者中可提高治疗效果、改善患者水潴留和血钠水平,且安全性较高,值得临床借鉴推广。
Objective To investigate the value of tolvaptan combined with sacubitril valsartan sodium in patients with chronic heart failure(CHF).Methods In this study,a total of 61 patients with CHF who were treated with basic therapy+sacubitril valsartan sodium+tolvaptan medication regimen in Juye County People’s Hospital from September 2020 to September 2023 were selected as the combined medication group,and 37 patients with CHF who were treated with basic therapy+sacubitril valsartan sodium medication regimen in our hospital during the same time period were selected as the single-medication group.Compare the efficacy,cardiac function and the occurrence of adverse reactions,and compare the 24 h urine volume and blood sodium level before and after treatment in the two groups.Results The total effective rate of treatment in the combined medication group was 91.80%(56/61),which was significantly higher than that of the single-medication group(75.68%)(28/37)(P<0.05).The American New York Heart Association(NYHA)Ⅰ~Ⅱin the combined medication group was 91.80%(56/61),which was significantly higher than 67.57%(25/37)of the single-medication group(P<0.05).Before treatment,the 24 h urine volume and blood sodium level showed no difference between two groups(P>0.05).After treatment,the 24 h urine volume and blood sodium level of the combined medication group were significantly higher than that of the single-medication group(P<0.05).No serious adverse reactions occurred during treatment in both groups.Conclusion Compared with single drug,the combination of tolvaptan and sacubitril valsartan sodium can improve the therapeutic effect,water retention and blood sodium level of patients,and the safety is high,which is worthy of clinical reference and promotion.
作者
刘欣
LIU Xin(Second Ward of Cardiovascular Medicine Department,Juye County People’s Hospital,Heze 274900,Shandong Province,China)
出处
《中国实用乡村医生杂志》
2024年第7期41-43,48,共4页
Chinese Practical Journal of Rural Doctor
